SCHEMBL4773794

SCHEMBL4773794

c1cc(-n2cnnn2)ccc1CN1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
CXCR4 P61073 10/20 0.50
NOTUM Q6P988 2/20 0.50
SIGMAR1 Q99720 1/20 0.50
MEN1 O00255 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
ADRA2C P18825 1/20 0.50
CCR2 P41597 1/20 0.50
CXCL12 P48061 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
F2 P00734 1/20 0.50
DPP4 P27487 1/20 0.49
DPP8 Q6V1X1 1/20 0.49
KCNH2 Q12809 3/20 0.47
KCNJ1 P48048 2/20 0.47
GPR119 Q8TDV5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2731943 0.78 KCNH2 (0.63) ALDH1A1KCNH2KCNJ1
Hydrochloric Acid SCHEMBL2731443 0.77 KCNH2 (0.62) ALDH1A1KCNH2KCNJ1
SCHEMBL14978749 0.76 TP53 (0.50) ALDH1A1NOTUMF2DPP4DPP8
SCHEMBL27569288 0.75 GBA1 (0.49) ALDH1A1NOTUMKMT2ATDP1F2
Hydrochloric Acid SCHEMBL5573232 0.75 CXCR4 (0.78) CXCR4SIGMAR1MEN1CHRM2CHRM1
SCHEMBL1259387 0.75 CXCR4 (0.81) ALDH1A1CXCR4SIGMAR1MEN1CHRM2
Hydrochloric Acid SCHEMBL4771571 0.74 GBA1 (0.47) ALDH1A1NOTUMKMT2ATDP1F2
SCHEMBL4777920 0.74 LMNA (0.49) ALDH1A1CXCR4NOTUMSIGMAR1F2
SCHEMBL15191990 0.73 KCNH2 (0.53) NOTUMSIGMAR1KMT2AKCNH2KCNJ1
Bromide SCHEMBL1257550 0.73 CXCR4 (0.78) ALDH1A1CXCR4SIGMAR1MEN1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 ALDH1A1 3228/4885CXCR4 25/4885NOTUM 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.